Association between
AHR
PBMC
PD1
PDAC
PDL1
immunotherapy
personalised
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 09 2023
19 09 2023
Historique:
received:
30
08
2023
revised:
15
09
2023
accepted:
18
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), has an immune suppressive environment that allows tumour cells to evade the immune system. The aryl-hydrocarbon receptor (AHR) is a transcription factor that can be activated by certain exo/endo ligands, including kynurenine (KYN) and other tryptophan metabolites. Once activated, AHR regulates the expression of various genes involved in immune responses and inflammation. Previous studies have shown that AHR activation in PDAC can have both pro-tumorigenic and anti-tumorigenic effects, depending on the context. It can promote tumour growth and immune evasion by suppressing anti-tumour immune responses or induce anti-tumour effects by enhancing immune cell function. In this study involving 30 PDAC patients and 30 healthy individuals, peripheral blood samples were analysed. PDAC patients were categorized into Low (12 patients) and High/Medium (18 patients)
Identifiants
pubmed: 37760608
pii: cancers15184639
doi: 10.3390/cancers15184639
pmc: PMC10526859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Baltic Research Programme, European Economic Area (EEA) States (Iceland and Liechtenstein) and Norway.
ID : S-BMT-21-9 (LT08-2-LMT-K-01-041)
Références
Nat Commun. 2020 Aug 11;11(1):4011
pubmed: 32782249
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
Cancers (Basel). 2021 Oct 08;13(19):
pubmed: 34638513
Sci Rep. 2021 Jan 18;11(1):1662
pubmed: 33462298
J Cell Biochem. 2008 May 15;104(2):402-17
pubmed: 18059014
Hum Vaccin Immunother. 2014;10(11):3354-68
pubmed: 25483688
Pharmaceuticals (Basel). 2021 Jun 23;14(7):
pubmed: 34201791
Oncogenesis. 2020 May 13;9(5):49
pubmed: 32404918
Medicine (Baltimore). 2018 Jan;97(3):e9617
pubmed: 29504990
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Int J Mol Sci. 2020 Dec 25;22(1):
pubmed: 33375613
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Biochem Biophys Res Commun. 2016 Mar 11;471(3):373-9
pubmed: 26869514
Adv Exp Med Biol. 2020;1248:33-59
pubmed: 32185706
Gut. 2018 Nov;67(11):2035-2044
pubmed: 28899983
Cancer Metastasis Rev. 2006 Sep;25(3):387-408
pubmed: 17043764
Cells. 2020 Feb 27;9(3):
pubmed: 32120774
Cancer Lett. 2017 Apr 10;391:38-49
pubmed: 28093284
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Cancer Cell. 2018 Mar 12;33(3):480-494.e7
pubmed: 29533786
Med Pharm Rep. 2021 Oct;94(4):402-410
pubmed: 36105495
Oncotarget. 2016 Feb 16;7(7):7747-60
pubmed: 26745602
Curr Opin Immunol. 2021 Jun;70:15-26
pubmed: 33429228
Arch Toxicol. 2017 Jul;91(7):2497-2513
pubmed: 28508231
Cancers (Basel). 2018 Jan 03;10(1):
pubmed: 29301364
J Biol Chem. 2023 Jun;299(6):104753
pubmed: 37116709
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncoimmunology. 2019 Apr 17;8(7):1601479
pubmed: 31143524
Front Oncol. 2022 Aug 11;12:958756
pubmed: 36033455
Annu Rev Immunol. 2014;32:403-32
pubmed: 24655296
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Cancers (Basel). 2023 Jan 05;15(2):
pubmed: 36672313
Int J Mol Sci. 2018 Nov 13;19(11):
pubmed: 30428588
Front Oncol. 2023 Jun 30;13:1142838
pubmed: 37456260
Int J Mol Sci. 2021 Jan 13;22(2):
pubmed: 33451095
Immunity. 2022 Feb 8;55(2):324-340.e8
pubmed: 35139353
Immunology. 2013 Feb;138(2):105-15
pubmed: 23216602
Ann Surg. 2016 Sep;264(3):429-36
pubmed: 27433903
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32503944
Oncotarget. 2020 Jun 23;11(25):2438-2461
pubmed: 32637034
BMC Cancer. 2020 Feb 13;20(1):120
pubmed: 32054467
Adv Cancer Res. 2019;143:63-144
pubmed: 31202363
Redox Biol. 2022 Aug;54:102350
pubmed: 35660630
Cytokine Growth Factor Rev. 2010 Oct;21(5):331-44
pubmed: 21115385
Front Immunol. 2019 Jul 31;10:1767
pubmed: 31417550
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
J Natl Cancer Inst. 2017 Jan 28;109(6):
pubmed: 28131992
J Int Med Res. 2018 Dec;46(12):5228-5236
pubmed: 30304975
Front Oncol. 2023 Apr 27;13:1165298
pubmed: 37182174
Int J Mol Sci. 2020 May 08;21(9):
pubmed: 32397303
Front Immunol. 2020 Jul 30;11:1644
pubmed: 32849564
Nat Commun. 2019 Mar 8;10(1):1125
pubmed: 30850589
Immunotherapy. 2014;6(10):1017-20
pubmed: 25428641
World J Gastroenterol. 2021 Jul 21;27(27):4298-4321
pubmed: 34366606
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Front Immunol. 2020 Sep 24;11:531491
pubmed: 33072086
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nat Rev Clin Oncol. 2020 Sep;17(9):527-540
pubmed: 32398706
Middle East J Dig Dis. 2019 Jan;11(1):38-44
pubmed: 31049181
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Semin Immunopathol. 2013 Nov;35(6):705-16
pubmed: 23942720
Diagnostics (Basel). 2021 Mar 20;11(3):
pubmed: 33804776
Gut. 2018 Jun;67(6):997-999
pubmed: 29217750
Oncotarget. 2015 Dec 1;6(38):41228-36
pubmed: 26515600
Adv Sci (Weinh). 2023 Aug 26;:e2303259
pubmed: 37632708
Innate Immun. 2013 Dec;19(6):631-43
pubmed: 23608822
Nat Neurosci. 2019 May;22(5):729-740
pubmed: 30962630
Front Oncol. 2020 Mar 24;10:382
pubmed: 32266154
J Immunother. 2015 Jan;38(1):1-11
pubmed: 25415283
Int J Mol Sci. 2021 Mar 15;22(6):
pubmed: 33804263
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33066260
Eur J Appl Physiol. 2021 Feb;121(2):637-644
pubmed: 33211154
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):453-454
pubmed: 34083798
Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):371-80
pubmed: 25100121
Nat Commun. 2020 Sep 24;11(1):4835
pubmed: 32973173
Nat Rev Drug Discov. 2022 Nov;21(11):799-820
pubmed: 35974096
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188387
pubmed: 32579889
Clin Cancer Res. 2016 May 15;22(10):2565-74
pubmed: 26719427
Chin Med J (Engl). 2020 Jan 20;133(2):148-153
pubmed: 31868801
Int J Mol Sci. 2019 Apr 11;20(7):
pubmed: 30979040
Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):95-100
pubmed: 29576277